• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by United Therapeutics Corporation

    2/10/25 10:25:38 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UTHR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    United Therapeutics Corporation

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    91307C102

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    91307C102


    1Names of Reporting Persons

    Wellington Management Group LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,224,216.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,463,891.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,463,891.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    91307C102


    1Names of Reporting Persons

    Wellington Group Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,224,216.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,463,891.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,463,891.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    91307C102


    1Names of Reporting Persons

    Wellington Investment Advisors Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,224,216.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,463,891.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,463,891.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    United Therapeutics Corporation
    (b)Address of issuer's principal executive offices:

    1000 Spring Street, Silver Spring MD 20910
    Item 2. 
    (a)Name of person filing:

    Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP
    (b)Address or principal business office or, if none, residence:

    c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
    (c)Citizenship:

    Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    91307C102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.
    (b)Percent of class:

    5.52  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Wellington Management Group LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:02/10/2025
     
    Wellington Group Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:02/10/2025
     
    Wellington Investment Advisors Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:02/10/2025
    Get the next $UTHR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UTHR

    DatePrice TargetRatingAnalyst
    4/25/2025Overweight → Equal Weight
    Wells Fargo
    4/21/2025$314.00Underperform → Neutral
    BofA Securities
    7/11/2024$310.00 → $321.00Overweight → Equal-Weight
    Morgan Stanley
    2/12/2024$213.00 → $215.00Sell → Neutral
    Goldman
    2/5/2024$330.00Outperform
    Leerink Partners
    12/8/2023$309.00Overweight
    Wells Fargo
    12/6/2022$320.00Buy
    UBS
    12/5/2022$230.00Sell
    Goldman
    More analyst ratings

    $UTHR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • United Therapeutics Corporation Reports First Quarter 2025 Financial Results

      United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout

      4/30/25 6:30:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

      Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented at a poster session United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Francisco on May 16-21, 2025. At ATS, United Therapeutics is sponsoring several events including the Respiratory Innovation Summit and the

      4/21/25 7:00:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

      United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and missi

      4/16/25 7:00:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • United Therapeutics downgraded by Wells Fargo

      Wells Fargo downgraded United Therapeutics from Overweight to Equal Weight

      4/25/25 8:31:30 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded United Therapeutics from Underperform to Neutral and set a new price target of $314.00

      4/21/25 8:09:51 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded United Therapeutics from Overweight to Equal-Weight and set a new price target of $321.00 from $310.00 previously

      7/11/24 7:48:56 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & GENERAL COUNSEL Mahon Paul A exercised 11,000 shares at a strike of $117.76 and sold $3,246,150 worth of shares (11,000 units at $295.10) (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      5/20/25 4:32:10 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thompson Tommy G exercised 2,500 shares at a strike of $175.43 and sold $762,865 worth of shares (2,500 units at $305.15) (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      5/12/25 4:30:23 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & GENERAL COUNSEL Mahon Paul A exercised 11,000 shares at a strike of $117.76 and sold $3,310,201 worth of shares (11,000 units at $300.93) (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      5/2/25 4:31:43 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Financials

    Live finance-specific insights

    See more
    • United Therapeutics Corporation Reports First Quarter 2025 Financial Results

      United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout

      4/30/25 6:30:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

      United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and missi

      4/16/25 7:00:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

      United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. "I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of that, our three-year cascade of clinical and regulatory events is under way: both TETON studies in idiopathic pulmonary fibrosis are enrolled, facilitating data starting the second half

      2/26/25 6:30:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Leadership Updates

    Live Leadership Updates

    See more
    • IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

      WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the

      1/27/21 8:00:00 AM ET
      $CLGN
      $UTHR
      $XERS
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $UTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation

      SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      11/8/24 4:30:29 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by United Therapeutics Corporation

      SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      10/16/24 1:03:48 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

      SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      6/10/24 12:15:17 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by United Therapeutics Corporation

      SCHEDULE 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      5/12/25 10:44:45 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)

      4/30/25 6:33:10 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by United Therapeutics Corporation

      10-Q - UNITED THERAPEUTICS Corp (0001082554) (Filer)

      4/30/25 6:32:05 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care